D'Wayne Wiggins, founding member of 'Tony! Toni! Tone!,' has died, family saysD'Wayne Wiggins, co-founder of Tony! Toni! Toné!, died at 64 from bladder cancer, leaving behind a legacy in music and mentorship.
D'Wayne Wiggins of the R&B group Tony! Toni! Tone!, dead at 64D'Wayne Wiggins, founding member of Tony! Toni! Tone!, has died at 64 after battling bladder cancer for over a year.
Tony! Toni! Tone! Co-Founder and Oakland Native D'Wayne Wiggins Has DiedD'Wayne Wiggins, of Tony! Toni! Tone!, passed away from bladder cancer at 64, leaving a significant impact on R&B and launching Destiny's Child.
D'Wayne Wiggins, founding member of the R&B group Tony! Toni! Tone!, has died at 64D'Wayne Wiggins, founding member of Tony! Toni! Tone!, has passed away at 64 after a battle with cancer, leaving a rich musical legacy.
D'Wayne Wiggins, founding member of 'Tony! Toni! Tone!,' has died, family saysD'Wayne Wiggins, co-founder of Tony! Toni! Toné!, died at 64 from bladder cancer, leaving behind a legacy in music and mentorship.
D'Wayne Wiggins of the R&B group Tony! Toni! Tone!, dead at 64D'Wayne Wiggins, founding member of Tony! Toni! Tone!, has died at 64 after battling bladder cancer for over a year.
Tony! Toni! Tone! Co-Founder and Oakland Native D'Wayne Wiggins Has DiedD'Wayne Wiggins, of Tony! Toni! Tone!, passed away from bladder cancer at 64, leaving a significant impact on R&B and launching Destiny's Child.
D'Wayne Wiggins, founding member of the R&B group Tony! Toni! Tone!, has died at 64D'Wayne Wiggins, founding member of Tony! Toni! Tone!, has passed away at 64 after a battle with cancer, leaving a rich musical legacy.
Dogs exposed to household chemicals more likely to get cancer, study findsHigher chemical exposure in dogs correlates with increased bladder cancer risk, which may also impact humans in shared environments.
Is a Smoker in Your House Killing Your Dog?Second-hand and third-hand smoke exposure poses serious health risks to dogs, increasing their chance of cancer and respiratory issues.
Pembrolizumab improves outcomes in high-risk bladder cancerPembrolizumab nearly doubles cancer-free duration post-invasive bladder surgery, offering a crucial treatment option for high-risk patients.
Combination Therapy May Improve Outcomes for Advanced Bladder Cancer - News CenterCombination therapy of pembrolizumab chemotherapy and oncolytic adenovirus shows promise for immunotherapy-resistant non-muscle-invasive bladder cancer.
Combination Treatment Extends Survival in Advanced Bladder Cancer - News CenterImmunotherapy combined with chemotherapy and surgery significantly improves survival in muscle-invasive bladder cancer patients compared to chemotherapy alone.
FDA approves bladder cancer treatment by Culver City companyFDA approved new bladder cancer treatment Anktiva by ImmunityBio, activating immune response in patients who didn't respond to prior therapies.
Pembrolizumab improves outcomes in high-risk bladder cancerPembrolizumab nearly doubles cancer-free duration post-invasive bladder surgery, offering a crucial treatment option for high-risk patients.
Combination Therapy May Improve Outcomes for Advanced Bladder Cancer - News CenterCombination therapy of pembrolizumab chemotherapy and oncolytic adenovirus shows promise for immunotherapy-resistant non-muscle-invasive bladder cancer.
Combination Treatment Extends Survival in Advanced Bladder Cancer - News CenterImmunotherapy combined with chemotherapy and surgery significantly improves survival in muscle-invasive bladder cancer patients compared to chemotherapy alone.
FDA approves bladder cancer treatment by Culver City companyFDA approved new bladder cancer treatment Anktiva by ImmunityBio, activating immune response in patients who didn't respond to prior therapies.
New Biomarker May Predict Treatment Response in Bladder Cancer - News CenterPatients with metastatic urothelial cancer and high NECTIN4 gene expression respond significantly better to enfortumab vedotin treatment.